Boston Scientific Corp (BSX)vsMeta Platforms Inc. (META)
BSX
Boston Scientific Corp
$53.93
-4.67%
HEALTHCARE · Cap: $84.08B
META
Meta Platforms Inc.
$609.63
-1.16%
COMMUNICATION SERVICES · Cap: $1.57T
Smart Verdict
WallStSmart Research — data-driven comparison
Meta Platforms Inc. generates 943% more annual revenue ($214.96B vs $20.61B). META leads profitability with a 32.8% profit margin vs 17.3%. BSX appears more attractively valued with a PEG of 0.68. META earns a higher WallStSmart Score of 83/100 (A-).
BSX
Strong Buy71
out of 100
Grade: B
META
Exceptional Buy83
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.6%
Fair Value
$46.16
Current Price
$53.93
$7.77 premium
Margin of Safety
+33.9%
Fair Value
$933.07
Current Price
$609.63
$323.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Strong operational efficiency at 20.6%
Mega-cap, among the largest globally
Every $100 of equity generates 33 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 40.6%
Revenue surging 33.1% year-over-year
Earnings expanding 62.4% YoY
Areas to Watch
No major concerns identified
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : META
The strongest argument for META centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 32.8% and operating margin at 40.6%. Revenue growth of 33.1% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : META
The primary concerns for META are Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a mature stock while META is a growth play — different risk/reward profiles.
META carries more volatility with a beta of 1.24 — expect wider price swings.
META is growing revenue faster at 33.1% — sustainability is the question.
META generates stronger free cash flow (13.2B), providing more financial flexibility.
Bottom Line
META scores higher overall (83/100 vs 71/100), backed by strong 32.8% margins and 33.1% revenue growth. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Meta Platforms Inc.
COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA
Meta Platforms, Inc. develops products that enable people to connect and share with friends and family through mobile devices, PCs, virtual reality headsets, wearables and home devices around the world. The company is headquartered in Menlo Park, California.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?